Erin Flynt

Bristol-Myers Squibb (United States) — United States

Medicine · Health Sciences

14h-index1.7kcitations157works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(151), Protein Degradation and Inhibitors(100), Peptidase Inhibition and Analysis(86), Research on Leishmaniasis Studies(20), Cancer Mechanisms and Therapy(13)

Publications157 total

Ktx-1001, a potent, selective MMSET/NSD2 inhibitor, enhances immunomodulatory and immune-directed therapies in preclinical models of multiple myeloma
Blood·2025
NSD2 inhibition suppresses t(4;14) gene expression and oncogenic signaling to impair proliferation in multiple myeloma
Blood·2025Open Access
Anti-Adhesion Properties of KTX-1001, a Selective NSD2/MMSET Inhibitor, Enhance Carfilzomib Sensitivity in Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
High Expression of NSD2 in Non t(4;14) Newly-Diagnosed Multiple Myeloma Patients May Mimic t(4;14) Biology
Clinical Lymphoma Myeloma & Leukemia·2025
Distinct patient, tumour and chimeric antigen receptor T‐cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma
British Journal of Haematology·2025· 1 citedOpen Access
Ktx-1029, a Potent, Selective MMSET/NSD2 Inhibitor Is Effective in t(4;14) Multiple Myeloma Preclinical Models
Blood·2024· 1 citedOpen Access
First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)
Blood·2024
Ectopic NSD2 Remodels H3K36me2 and DNA Methylation to Promote Oncogenic Gene Expression in Multiple Myeloma
Blood·2024
A Mass Cytometry-Based Clinical Pharmacodynamic Assay for Histone 3 Lysine 36 Dimethyl (H3K36me2) Levels in Myeloma Cells and Peripheral Blood for Implementation in NSD2 Inhibitor Ktx-1001 First in Human Trial in Relapsed and Refractory Multiple Myeloma
Blood·2024
Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma
Cell Reports Medicine·2024· 14 citedOpen Access
Pharmacodynamic changes in tumor and immune cells drive iberdomide’s clinical mechanisms of activity in relapsed and refractory multiple myeloma
Cell Reports Medicine·2024· 12 citedOpen Access
Supplementary Table S1 from ETV4-Dependent Transcriptional Plasticity Maintains <i>MYC</i> Expression and Results in IMiD Resistance in Multiple Myeloma
2024Open Access
Supplementary Data 6 from ETV4-Dependent Transcriptional Plasticity Maintains <i>MYC</i> Expression and Results in IMiD Resistance in Multiple Myeloma
2024Open Access
Data from ETV4-Dependent Transcriptional Plasticity Maintains <i>MYC</i> Expression and Results in IMiD Resistance in Multiple Myeloma
2024Open Access
Supplementary Table S2 from ETV4-Dependent Transcriptional Plasticity Maintains <i>MYC</i> Expression and Results in IMiD Resistance in Multiple Myeloma
2024Open Access
Supplementary Figures S1-S11 from ETV4-Dependent Transcriptional Plasticity Maintains <i>MYC</i> Expression and Results in IMiD Resistance in Multiple Myeloma
2024Open Access
Supplementary Data 5 from ETV4-Dependent Transcriptional Plasticity Maintains <i>MYC</i> Expression and Results in IMiD Resistance in Multiple Myeloma
2024Open Access
Supplementary Data 4 from ETV4-Dependent Transcriptional Plasticity Maintains <i>MYC</i> Expression and Results in IMiD Resistance in Multiple Myeloma
2024Open Access
Supplementary Data 7 from ETV4-Dependent Transcriptional Plasticity Maintains <i>MYC</i> Expression and Results in IMiD Resistance in Multiple Myeloma
2024Open Access
Supplementary Data 6 from ETV4-Dependent Transcriptional Plasticity Maintains <i>MYC</i> Expression and Results in IMiD Resistance in Multiple Myeloma
2024Open Access
page 1 of 8Next →

Frequent Co-authors

Anjan Thakurta(45), Brian A. Walker(24), Gareth J. Morgan(23), Cody Ashby(19), Fadi Towfic(19), Sarah Gooding(15), Nicholas Stong(14), María Ortiz(13), Naser Ansari‐Pour(12), William E. Pierceall(12), Frits van Rhee(11), Matthew Trotter(10), Karthik Ramasamy(10), Mohammad H. Kazeroun(10), Kwee Yong(10), Aarif Ahsan(10), Michael Bauer(9), Mehmet Samur(9), Sagar Lonial(9), Evelyn Fitzsimons(9)